Stay updated on Abemaciclib Pembrolizumab in Head and Neck Cancer Clinical Trial
Sign up to get notified when there's something new on the Abemaciclib Pembrolizumab in Head and Neck Cancer Clinical Trial page.

Latest updates to the Abemaciclib Pembrolizumab in Head and Neck Cancer Clinical Trial page
- CheckyesterdayChange DetectedRevision: v3.3.4 replaces v3.3.3 for the Study Protocol and SAP document.SummaryDifference0.1%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedAdded a Locations section with the Alabama site (Birmingham). Updated the page revision to v3.3.3 and removed the HHS Vulnerability Disclosure footer link.SummaryDifference0.2%

- Check51 days agoChange DetectedThe page now displays revision: v3.3.2 and no longer shows v3.2.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check59 days agoChange DetectedRemoved the government funding/operating status notice banner. The core study details remain unchanged.SummaryDifference0.4%

- Check80 days agoChange DetectedNo additions or deletions affecting core study details or page purpose were detected.SummaryDifference0.5%

- Check102 days agoChange DetectedAdded a government funding lapse notice and a v3.2.0 version tag, replacing the prior v3.1.0.SummaryDifference3%

Stay in the know with updates to Abemaciclib Pembrolizumab in Head and Neck Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Abemaciclib Pembrolizumab in Head and Neck Cancer Clinical Trial page.